Pharma Focus Asia

Mundipharma enters into partnership with Samsung Bioepis to expand Biosimilars to Hong Kong and Taiwan

Saturday, January 18, 2020

Mundipharma today announced a partnership with Samsung Bioepis to commercialize the first biosimilar candidates from Samsung Bioepis in Taiwan and Hong Kong.

The partnership includes biosimilar candidates from Samsung Bioepis in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).

The partnership makes Mundipharma the exclusive commercialization partner, while Samsung Bioepis remains the marketing authorization holder (MAH), who is responsible for the clinical development, legal registration and production of the biosimilars.

" This partnership combines the proven biosimilar development platform of Samsung Bioepis with the commercial insight and market insight of Mundipharma and the ability to improve patients' access to proven treatments," said Raman Singh, CEO of Mundipharma. " This partnership will help meet the needs of patients for immunology and oncology treatments in two key areas in Asia," he added.

This announcement is officially valid in the original source language. Translations are only intended as reading aids and must be compared with the text in the source language, which is the only one valid.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024